BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. Its lead product, BLU-5937, is being developed for the treatment of chronic cough and other afferent hypersensitization-related disorders.
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.